Literature DB >> 20199875

Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients.

Ramanath Dukkipati1, Csaba P Kovesdy, Sara Colman, Matthew J Budoff, Allen R Nissenson, Stuart M Sprague, Joel D Kopple, Kamyar Kalantar-Zadeh.   

Abstract

BACKGROUND: Low serum parathyroid hormone (PTH) has been implicated as a primary biochemical marker of adynamic bone disease in individuals with chronic kidney disease (CKD) who undergo maintenance hemodialysis (MHD) treatment. We hypothesized that the malnutrition-inflammation complex is associated with low PTH levels in these patients and confounds the PTH-survival association.
METHODS: We examined 748 stable MHD outpatients in southern California and followed them for up to 5 years (October 2001-December 2006).
RESULTS: In 748 MHD patients, serum PTH <150pg/mL was more prevalent among non-blacks and diabetics. There was no association between serum PTH and coronary artery calcification score, bone mineral density, or dietary protein or calorie intake. Low serum PTH was associated with markers of protein-energy wasting and inflammation, and this association confounded the relationship between serum PTH and alkaline phosphatase. Although 5-year crude mortality rates were similar across PTH increments, after adjustment for the case-mix and surrogates of malnutrition and inflammation, a moderately low serum PTH in 100-150pg/mL range was associated with the greatest survival compared to other serum PTH levels, i.e., a death hazard ratio of 0.52 (95% confidence interval: 0.29-0.92, p<0.001) compared to PTH of 300-600pg/mL (reference).
CONCLUSIONS: Low serum PTH may be another facet of the malnutrition-inflammation complex in CKD, and after controlling for this confounder, a moderately low PTH in 100-150pg/mL range appears associated with the greatest survival. Limitations of observational studies should be considered. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20199875      PMCID: PMC3175364          DOI: 10.1053/j.jrn.2009.10.006

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  62 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients.

Authors:  Kamyar Kalantar-Zadeh; Noriko Kuwae; Dennis Y Wu; Ronney S Shantouf; Denis Fouque; Stefan D Anker; Gladys Block; Joel D Kopple
Journal:  Am J Clin Nutr       Date:  2006-02       Impact factor: 7.045

Review 3.  Adynamic bone revisited: is there progress?

Authors:  Cheryl P Sanchez
Journal:  Perit Dial Int       Date:  2006 Jan-Feb       Impact factor: 1.756

4.  Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity.

Authors:  Peter Stenvinkel; Olof Heimbürger; Tomas Jogestrand
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

5.  A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients.

Authors:  S Beddhu; F J Bruns; M Saul; P Seddon; M L Zeidel
Journal:  Am J Med       Date:  2000-06-01       Impact factor: 4.965

6.  Number of days of food intake records required to estimate individual and group nutrient intakes with defined confidence.

Authors:  P P Basiotis; S O Welsh; F J Cronin; J L Kelsay; W Mertz
Journal:  J Nutr       Date:  1987-09       Impact factor: 4.798

Review 7.  Adynamic bone disease: an update and overview.

Authors:  Giorgio Coen
Journal:  J Nephrol       Date:  2005 Mar-Apr       Impact factor: 3.902

Review 8.  The biology of cachectin/TNF--a primary mediator of the host response.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

9.  Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.

Authors:  Deborah L Regidor; Csaba P Kovesdy; Rajnish Mehrotra; Mehdi Rambod; Jennie Jing; Charles J McAllister; David Van Wyck; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 10.121

10.  Obesity is associated with secondary hyperparathyroidism in men with moderate and severe chronic kidney disease.

Authors:  Csaba P Kovesdy; Shahram Ahmadzadeh; John E Anderson; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2007-08-08       Impact factor: 8.237

View more
  32 in total

1.  Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients.

Authors:  Jessica E Miller; Csaba P Kovesdy; Keith C Norris; Rajnish Mehrotra; Allen R Nissenson; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2010-09-03       Impact factor: 3.754

Review 2.  Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.

Authors:  Kamyar Kalantar-Zadeh; Anuja Shah; Uyen Duong; Rulin C Hechter; Ramanath Dukkipati; Csaba P Kovesdy
Journal:  Kidney Int Suppl       Date:  2010-08       Impact factor: 10.545

Review 3.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

4.  Active vitamin D and acute respiratory infections in dialysis patients.

Authors:  Yoshihiro Tsujimoto; Hideki Tahara; Tetsuo Shoji; Masanori Emoto; Hidenori Koyama; Eiji Ishimura; Tsutomu Tabata; Yoshiki Nishizawa; Masaaki Inaba
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

5.  Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism.

Authors:  Bojan Kovacevic; Mile Ignjatovic; Vladan Zivaljevic; Vladimir Cuk; Milena Scepanovic; Zaklina Petrovic; Ivan Paunovic
Journal:  Langenbecks Arch Surg       Date:  2012-01-13       Impact factor: 3.445

6.  Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease.

Authors:  Lilia R Lukowsky; Miklos Z Molnar; Joshua J Zaritsky; John J Sim; Istvan Mucsi; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2011-12-29       Impact factor: 5.992

Review 7.  Parathyroidectomy in the Management of Secondary Hyperparathyroidism.

Authors:  Wei Ling Lau; Yoshitsugu Obi; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-09       Impact factor: 8.237

Review 8.  Survival disparities within American and Israeli dialysis populations: learning from similarities and distinctions across race and ethnicity.

Authors:  Kamyar Kalantar-Zadeh; Eliezer Golan; Tamy Shohat; Elani Streja; Keith C Norris; Joel D Kopple
Journal:  Semin Dial       Date:  2010 Nov-Dec       Impact factor: 3.455

Review 9.  Insights into nutritional and inflammatory aspects of low parathyroid hormone in dialysis patients.

Authors:  Usama Feroze; Miklos Z Molnar; Ramanath Dukkipati; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  J Ren Nutr       Date:  2011-01       Impact factor: 3.655

Review 10.  Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology.

Authors:  Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino
Journal:  J Nephrol       Date:  2016-04-09       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.